Retail prices on several anti-cancer medications slashed
The retail prices of some anti-cancer drugs have been cut by 87 percent by the drug price control authority in India.
List view / Grid view
The retail prices of some anti-cancer drugs have been cut by 87 percent by the drug price control authority in India.
18 August 2016 | By The National Institute for Health and Care Excellence (NICE)
In new draft guidance, the National Institute for Health and Care Excellence (NICE) has advised that everolimus, for treating advanced breast cancer after endocrine therapy, and ibrutinib, for treating relapsed or refractory mantle cell lymphoma, two drugs on the Cancer Drugs Fund are not cost effective.